In this new post-hoc analysis (planned after the study closed) of the SPARCL study, kidney function was evaluated by estimated glomerular filtration rate (eGFR, mL/min/1.
In the SPARCL study, patients with chronic kidney disease had higher risk of stroke (27 percent) or major coronary events (70 percent) compared to patients without chronic kidney disease.
The SPARCL study (n=4,731), published in the New England Journal of Medicine in 2006, is the only study to date evaluating the benefits of a statin solely in patients with a prior stroke or mini-stroke.
An additional analysis evaluated 781 patients in the SPARCL trial who were classified as having metabolic syndrome and who had a recent stroke or mini-stroke but no known coronary heart disease.
The SPARCL study, published in the New England Journal of Medicine in 2006, is the only study to date evaluating statin therapy exclusively for patients with recent stroke or mini-stroke and no coronary heart disease (n=4,731).
A new SPARCL analysis was conducted to evaluate if treatment with Lipitor 80 mg was associated with significant protection from coronary events after a recurrent stroke or mini-stroke.
The benefits of Lipitor 80 mg in patients with a recurrent stroke or mini-stroke seen in this analysis are consistent with the primary SPARCL results which demonstrated the benefit of Lipitor 80 mg in reducing stroke and coronary events among all patients in the study (n=4,731).
The SPARCL study enrolled 4,731 patients who had no history of heart disease and had experienced a stroke or TIA (mini-stroke) within six months prior to trial enrollment.
A separate analysis of the SPARCL data that was designed and conducted after the study ended showed that patients taking Lipitor experienced a 22 percent reduction in the risk of ischemic stroke," said Uskavitch.